NORTH LIBERTY, Iowa, Aug. 30, 2011 (GLOBE NEWSWIRE) -- KemPharm, Inc. (“KemPharm”) today announced it plans to initiate development of its recently identified lead compound KP415, a first-in-class prodrug of methylphenidate, which is a commonly used medication for the treatment of attention-deficit hyperactivity disorder (ADHD). KP415 was identified using KemPharm’s Ligand Activated Therapy (LAT) approach. KP415 is the second product candidate in KemPharm’s ADHD portfolio, which also includes KP106, a prodrug of d-amphetamine that has successfully completed a clinical proof-of-concept trial against Vyvanse®. KemPharm is actively seeking a pharmaceutical partner for late-stage clinical development and commercialization of its novel ADHD franchise.
